Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Closed Solicitation Posted
- Solicitation number
- HT9402-24-Q-9401
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- San Antonio, Texas 78230, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Defense (DoD) is issuing a Request for Quotation (RFQ) for pharmaceutical agents within specific drug classes to be considered for placement on the DoD Uniform Formulary (UF). The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the decisions of the DoD Pharmacy and Therapeutics (P&T) Committee. The drug classes under review include Migraine Agents: Oral CGRP, Targeted Immunomodulatory Biologics: Interleukin 17, and Targeted Immunomodulatory Biologics: Interleukin 23. Manufacturers must submit quotes by September 19, 2024, and respond to clinical questions by the date stated in the RFQ. A pre-quote teleconference is scheduled for July 24, 2024.
This solicitation is not set-aside for any specific business type. The Defense Health Agency is the issuing agency. The place of performance is San Antonio, TX 78230, USA. The NAICS code is 325412 - Pharmaceutical Preparation Manufacturing, and the PSC code is 6505 - Drugs And Biologicals. The RFQ does not provide any information about potential incumbents or current contractors, award values, or budget ranges.
Notice text
2 versions
Update #2 · Latest ·
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS} which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21} describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF} and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF}, Extended Core Formulary (ECF), or nonformulary (NF). Prior to the scheduled P& T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA} and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: November 2024: The following drug classes/subclass will be reviewed:
a. MIGRAINE AGENTS: ORAL CGRP
Nurtec ODT
Qulipta
Ubrelvy
b. TARGETED IMMUNOMODULATORY BIOLOGICS: INTERLEUKIN 17
Cosentyx
Siliq
Taltz
Bimzelx
c. TARGETED IMMUNOMODULATORY BIOLOGICS: INTERLEUKIN 23
Ilumya
Skyrizi
Stelara
Tremfya
Omvoh
The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-24-Q-9401.
Pre-quote teleconference is on July 24, 2024. Details are stated in Part 2.5. Pre quotation teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via email to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.
Update #1 ·
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS} which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21} describe the process by which the DoD Pharmacy and Therapeutics (P& T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF} and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF}, Extended Core Formulary (ECF), or nonformulary (NF). Prior to the scheduled P& T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA} and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P & T COMMITTEE MEETING: November 2024: The following drug classes/subclass will be reviewed:
a. MIGRAINE AGENTS: ORAL CGRP
Nurtec ODT
Qulipta
Ubrelvy
b. TARGETED IMMUNOMODULATORY BIOLOGICS: INTERLEUKIN 17
Cosentyx
Siliq
Taltz
Bimzelx
c. TARGETED IMMUNOMODULATORY BIOLOGICS: INTERLEUKIN 23
Ilumya
Skyrizi
Stelara
Tremfya
Omvoh
The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-24-Q-9401.
Pre-quote teleconference is on July 24, 2024. Details are stated in Part 2.5. Pre quotation teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via email to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.
Files
| File | Type | Posted |
|---|---|---|
| Amendment 0002.pdf | ||
| Amend 0002 RFQ HT9402-24-Q-9401.pdf | ||
| Amend 0001 November 2024 PT Meeting Reporting.xlsx | XLSX spreadsheet | |
| Amendment 0001.pdf | ||
| RFQ HT9402-24-Q-9401 CR.pdf | ||
| NDC Price List - TIBS - IL 23.xlsx | XLSX spreadsheet | |
| NDC Price List FAQ Class Review.pdf | ||
| NDC Price List - Migraine Agents - Oral CGRP.xlsx | XLSX spreadsheet | |
| NDC Price List - TIBS - IL 17.xlsx | XLSX spreadsheet | |
| November 2024 PT Meeting Reporting.xlsx | XLSX spreadsheet |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity